Immuneering has reported updated data on atebimetinib in first-line pancreatic cancer patients, linking the MEK inhibitor to ...

Reported 12-month overall survival (OS) in Phase 2a clinical trial nearly double the benchmark from pivotal study of standard ...

Immuneering shares traded lower after new pancreatic cancer trial data showed improved survival, manageable safety, and key ...

Mizuho analyst Graig Suvannavejh said, though the overall survival rate was encouraging, it was much lower than the six-month rate of 94% or the nine-month rate of 86%, "reflecting a greater ...

Irene Blair was expected to have another six to eight months to live in June, after her pancreatic cancer rapidly advanced to ...

Immuneering (NASDAQ:IMRX) provided an update from its ongoing Phase 2A trial of atebumetanib plus modified gemcitabine and ...

BullFrog AI's bfLEAP platform identified biomarkers linked to improved survival in pancreatic adenocarcinoma patients treated with glufosfamide. The study revealed four patient clusters, with one ...

The world’s first early-detection blood test for pancreatic cancer is set to be launched in Australia, and is predicted to ...

A new study explains how pancreatic tumors use a sugar coating to hide from the immune system and shows that a newly ...

Despite being diagnosed with what he himself referred to as a "death sentence," the former U.S. senator declared that he's ...